# A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Study · id `cardio:ct-nct02206165` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02206165](<https://clinicaltrials.gov/study/NCT02206165>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02206165

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 456 participants.

## Technical summary

Registry record NCT02206165. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 456 participants (planned count; ClinicalTrials.gov record NCT02206165, source copy `cardio:ctgov-nct02206165-2015-03-30`, retrieved 2026-10-26)
- Start date: 2014-03 (registry gives no type) (ClinicalTrials.gov record NCT02206165, source copy `cardio:ctgov-nct02206165-2015-03-30`, retrieved 2026-10-26)
- Primary completion: 2015-04 (anticipated) (ClinicalTrials.gov record NCT02206165, source copy `cardio:ctgov-nct02206165-2015-03-30`, retrieved 2026-10-26)
- Completion: 2015-06 (anticipated) (ClinicalTrials.gov record NCT02206165, source copy `cardio:ctgov-nct02206165-2015-03-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02206165, source copy `cardio:ctgov-nct02206165-2015-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02206165-2015-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Candesartan 8mg
- Intervention (Drug): Candesartan 16mg
- Intervention (Drug): Amlodipine 5mg
- Intervention (Drug): Amlodipine 10mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: ea1a0ee0f49fae86484cb15db41a3856cb4ab691e7f553cadff9b5ea6199c53b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
